Announcement PDF EGM Presentation – August 2024 RADIOPHARM THERANOSTICS LTD 2024 1 IMPORTANT NOTICE AND DISCLAIMER The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law. This presentation is not a prospectus or other disclosure document under the Corporations Act 2001 (Cth) and will not be lodged with the Australian Securities and Investments Commission. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this presentation, you should observe such restrictions as any non-compliance with these restrictions could contravene applicable securities laws (see the section captioned ‘International offer restrictions’). In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change. RADIOPHARM THERANOSTICS LTD 2024 | 2 RAD IS AT THE CUTTING EDGE OF RADIOPHARMACEUTICALS, A TRANSFORMATIVE MODALITY WITHIN CANCER TREATMENT 1 Differentiated Within Radiopharmaceuticals • Clinical-stage company with deep pipeline of radiotherapeutic assets pursuing novel targets, leveraging insights from ADCs, using innovative targeting moieties such as nanobodies – – 2 3 4 5 Targets include PD-L1, HER2, TROP2 (nanobody platform); integrin αVβ6 (peptide) fatty acid synthase (small molecule) Preclinical technologies (mAb-based) Radiopharm Ventures, a Joint Venture with MD Anderson Cancer Center • • JV (private company) in-licensed from MDACC technologies for radiopharmaceuticals use First technology has been disclosed (B7H3-targeting molecule) Radiopharmaceuticals Expertise, In licensing Strategy & Intellectual Property • • • • All team members with previous imaging and therapeutic radiopharmaceutical experience Extensive Scientific Advisory Board of accredited multinational researchers Proprietary molecules designed to identify and target a broad range of malignancies in solid tumors Extensive patent portfolio for targets through 2040 Lantheus Strategic Investment • Lantheus Holdings, Inc (LNTH.NASDAQ, Market Cap approximately US$7Bn) has entered into agreement with Radiopharm to invest, subject to shareholder approval, ~A$7.6m. Shares to be acquired at A$0.05, which represents a ~47% premium to the last closing price on 19 June 2024 and a ~57% premium to the 5day VWAP. Option to invest a further ~A$7.6m within 6 months • Under a separate agreement, Lantheus has secured rights over two early preclinical assets in exchange for a ~A$3m upfront payment Strong Cash and Funding Position Post Capital Raising • A$70.0m raised via a two-tranche placement at an Offer Price of A$0.04 per share, representing a 17.6% premium to the closing price of Radiopharm’s shares on 19 June 2024 • • Subject to shareholder approval, Executive Chairman, Paul Hopper, will be participating for A$3m under the Offer Post completion of the capital raise, Radiopharm will be fully funded to support its current clinical programs beyond mid 2026 RADIOPHARM THERANOSTICS LTD 2024 | 3 LANTHEUS STRATEGIC INVESTMENT Lantheus Holdings Inc (LNTH.NASDAQ, market cap approximately US$7Bn) is a global leader in the development, manufacture and commercialisation of diagnostic and therapeutic radiopharmaceutical products with offices in Massachusetts, New Jersey, Canada and Sweden. Lantheus is investing ~A$7.6m into Radiopharm Shares to be acquired at $0.05 per share. A ~57% premium to the 5-day VWAP Lantheus will secure rights over two early preclinical assets for a A$3m upfront payment Global rights for RAD 206 Development (TROP-2) and RAD 502 (DUNP19) in exchange for a A$3 million upfront payment Option to invest a further ~A$7.6m within 6 months Additional investment to be made at $0.05 per share. A ~57% premium to the 5-day VWAP * Subject to shareholder approval. Shares subscribed for by Lantheus will be escrowed for 12 months from allotment date * Assumes an AUD/USD exchange rate of $0.66 “We are pleased to make a strategic investment in RAD and partner with them to further expand our innovative pipeline. Radiopharmaceutical theranostics are changing the way cancer is diagnosed and treated, yet we still have more work to do and are inspired to further advance this field with these two preclinical oncology assets.” Brian Markison, Chief Executive Officer of Lantheus RADIOPHARM THERANOSTICS LTD 2024 | 4 RADIOPHARMACEUTICALS DELIVER RADIATION DIRECTLY TO CANCER CELLS CANCER CELL LINKER TARGET TARGETING MOLECULE RADIOACTIVE ISOTOPE Building Blocks of Radiopharmaceuticals Considerations Targeting Molecule (high affinity small molecule, peptide or antibody) Serum half-life, immunogenicity, tumor uptake and retention, plasma clearance (especially via renal system) Radioactive Isotope (imaging / therapeutic) Target heterogeneity, tissue anatomy, desired cross-fire effect, mechanism of cytotoxicity, imaging properties Linker (joins targeting molecule and radioactive isotope) Stability, uptake in desired versus undesired organs Imaging Therapeutics SEE and measure disease with radioactive isotopes TREAT cancer with high energy particle emitters Imaging compounds precisely deliver radioactive isotopes to detect and image cancer cells Very high selectivity to cancer cells while limiting damage to healthy tissues RADIOPHARM THERANOSTICS LTD 2024 | 5 EXPANDING RADIOPHARMACEUTICAL TARGETS AND INDICATIONS Novel Radiopharmaceutical Targets With Validated Biology beyond PSMA, SSTR2, FAPI PD-L1, HER2, (nanobodies); αVβ6 Integrin (peptide), fatty acid synthase (small molecule) Tuned Isotope Selection Lu177 (beta), Ac225 (alpha), Tb161 (beta + Auger) Optimized Binding Moieties Supply Chain Enhancement Nanobodies, high affinity peptides, small molecules RADIOPHARM THERANOSTICS LTD 2024 | 6 COMPANY PIPELINE PROGRAM RAD204 RAD202 RAD301 RAD302 TARGET & MOLECULE PD-L1 (Nanobody) HER 2 (Nanobody) Integrin αVβ6 (Peptide) INDICATION Dx/Tx ISOTOPE NON-SMALL CELL LUNG CANCER Therapy Lu177 Phase 1 enrolling in Australia, NCT06305962 BREAST / GASTRIC CANCER Therapy Lu177 Ethics approval in Q3 2024 Phase 1 trial starting in Q4 2024 Imaging Ga68 Phase 1 enrolling in the US, NCT05799274 Therapy Lu177 Phase 1 trial planned in 2025 PRECLINICAL PHASE I PHASE II NOTES PANCREATIC CANCER Phase 2a Phase 2b RAD101 RAD102 RAD402 RV01 Fatty Acid Synthase Imaging F18 IND approval received for Phase 2b in US (n=30) Therapy I123 Preclinical studies progressing PROSTATE Therapy Tb161 CMC production, BioD, GLP Tox studies ongoing Multiple Solid Tumors Therapy Lu177 CMC production, BioD, GLP Tox studies ongoing BRAIN METS (Small Molecule) KLK3 (mAb) B7H3 (mAb) RADIOPHARM THERANOSTICS LTD 2024 | 7 Compassionate use and Imaging trials derisked clinical development: 172 patients already dosed PRE-CLINICAL COMPASSIONATE USE Pivalate F18 Small molecule RAD 101 Integrins Peptide RAD 301 n=99 Imaging PHASE 1 PHASE 1/2 PHASE 2/2b PHASE 2/3 n=24 Imaging n=17 Imaging Phase 2a 2H2024 n=30 Imaging 2026 n=150 Imaging 1H 2025 n=30 2026 n=100 Imaging n= 9 Imaging PD-L1 Nanobody RAD 204 n=16 Imaging n=27 Phase 1 Therapeutic 1H 2026 n=50 Therapeutic Her-2 Nanobody RAD 202 n=16 Imaging 2H2024 n=21 Phase 1 Therapeutic 2h2026 n=50 Therapeutic PSA Antibody 402 2H 2025 n=21 Phase 1 Therapeutic B7H3 Antibody RV01 2H 2025 n=21 Phase 1 Therapeutic Pre-Clinical Completed Recruiting Future RADIOPHARM THERANOSTICS LTD 2024 8 Upcoming Milestones: 4 data read-outs in the next 18-24 months 1H 2024 2H 2024 1H 2025 2H 2025 1H 2026 PROGRAM TARGET & MOLECULE INDICATION Dx/Tx ISOTOPE RAD204 PD-L1 (Nanobody) NON-SMALL CELL LUNG CANCER Therapy Lu177 RAD202 HER 2 (Nanobody) BREAST / GASTRIC CANCER Therapy Lu177 Imaging Ga68 Therapy Lu177 Imaging F18 Therapy I123 PROSTATE Therapy Tb161 P1 in Aus MULTIPLE SOLID TUMORS Therapy Lu177 P1 in USA RAD301 RAD302 RAD101 RAD102 RAD402 RV01 Integrin αVβ6 (Peptide) Fatty Acid Synthase (Small Molecule) KLK3 (mAb) B7H3 (mAb) PANCREATIC CANCER P1 in Aus read-out P1 in Aus P1 in USA read-out read-out P1 in USA P2b in USA read-out BRAIN METS P1 in USA RADIOPHARM THERANOSTICS LTD 2024 | 9 RADIOPHARM THERANOSTICS LTD 2024 10